Hyperkalemia
Use of SGLT2i with RAASi is associated with reduced risk for hyperkalemia in the clinical setting, a study found.
A study compared the risks of cardiovascular events in hospital settings among patients with CKD with and hyperkalemia.
Can SZC help with RAASi maximization without resultant hyperkalemia in patients with HFrEF and CKD?
Wei Ling Lau, MD, discussed the potential impact of AccurKardia's AK+ Guard hyperkalemia detection software.
Could the use of potassium binder SZC with dialysate potassium reduce postdialysis heart arrhythmias?
Researchers estimated hyperkalemia incidence in patients with chronic kidney disease from routine clinical care.
A study assessed the efficacy and safety of hyperkalemia treatment and identified risk factors associated with hypoglycemia.
Hyperkalemia and metabolic acidosis are common with CKD, and the potassium binder SZC may have benefits for both.
Data from DISCOVER CKD was used to assess the burden and real-world treatment of hyperkalemia in CKD patients.
A study explored the relationship between intake of dietary fiber and hyperkalemia in patients on maintenance hemodialysis.
Researchers assessed the landscape of QSP modeling and developed a use case for QSP to determine hyperkalemia risk.
Researchers examined the impact of a local guideline recommending use of SZC in patients with moderate hyperkalemia.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.